GKOS - NYSE

Glaukos Corporation

GKOS·NYSE

$113.64

+2.6%

HealthcareMedical - Devices

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.67B

EPS-3.2800

P/E Ratio-34.65

Earnings Date07/29/2026

893.49M

Assets

-8%

3Y-17.0%

5Y-11.0%

10Y+565.0%

237.33M

Total Liabilities

14%

3Y-56.0%

5Y-30.0%

10Y+1288.0%

656.15M

Total Equity

-14%

3Y+24.0%

5Y-2.0%

10Y+460.0%

Glaukos Corporation Funding & Solvency Profile

GKOS · NYSE

Current Assets

Cash & Cash Equivalents90.81M

Net Receivables108.61M

Inventory63.56M

Other Current Assets24.05M

Total Current Assets475 M

Non-Current Assets

Property, Plant & Equipment184.18M

Goodwill & Intangible Assets208.63M

Long-Term Investments3.83M

Other Non-Current Assets21.86M

Total Non-Current Assets210 M

Total Assets

893.49M

Financial Health Analysis

Current Ratio

4.69x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.36x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

374 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

53% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Glaukos Corporation Balance Sheet

GKOS • NYSE

Glaukos Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	90.8M	169.6M	93.5M	119.5M	100.7M	96.6M	62.4M	29.8M	24.5M	6.5M	21.6M	2.3M	6.7M	1.7M
Short-Term Investments	187.9M	149.3M	202M	233.2M	313.3M	307.8M	111.6M	110.7M	94.5M	89.3M	69.6M	0.0	0.0	0.0
Cash & Short-Term Investments	278.8M	318.9M	295.4M	352.7M	414.1M	404.4M	174M	140.5M	119M	95.8M	91.1M	2.3M	6.7M	1.7M
Net Receivables	108.6M	60.7M	39.9M	36.1M	33.4M	36.1M	38.4M	18.7M	16.7M	14.3M	7.5M	5.4M	2.9M	552K
Accounts Receivables	108.6M	60.7M	39.9M	36.1M	33.4M	36.1M	38.4M	18.7M	16.7M	14.3M	7.5M	5.4M	2.9M	0.0
Inventory	63.6M	57.7M	42M	37.8M	23M	15.8M	42.6M	13.3M	11.2M	6.8M	4.1M	2.3M	1.9M	915K
Prepaids	0.0	0.0	0.0	0.0	0.0	0.0	7.9M	4.1M	2.6M	3M	1.3M	534K	426K	0.0
Other Current Assets	24.1M	12.5M	18.2M	17.3M	15.6M	13.2M	0.0	4.1M	2.6M	80K	80K	60K	60K	323K
Total Current Assets	475M	449.8M	395.5M	443.9M	486.1M	469.4M	262.9M	176.6M	149.5M	120M	104.1M	10.6M	12M	3.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	184.2M	169.9M	174.5M	166.8M	146.1M	95.5M	91.8M	19.2M	11.8M	7.6M	2.2M	2M	1.9M	1.6M
Goodwill	66.7M	66.1M	66.1M	66.1M	66.1M	66.1M	66.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	141.9M	263.4M	283M	307.9M	332.8M	357.7M	382.6M	0.0	3.1M	6.6M	10.2M	13.5M	17M	0.0
Goodwill & Intangible Assets	208.6M	329.6M	349.1M	374M	398.9M	423.8M	448.7M	-8.8M	3.1M	6.6M	10.2M	13.5M	17M	0.0
Long-Term Investments	3.8M	0.0	0.0	7.1M	9.4M	9.6M	0.0	8.8M	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	71.8M	79.1M	0.0	0.0	213K	235K	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	21.9M	25.4M	21.3M	10.6M	9.1M	7.2M	15M	11M	1.2M	188K	149K	42K	77K	-1.6M
Total Non-Current Assets	418.5M	525M	545M	630.3M	642.7M	536.1M	555.5M	30.4M	16.4M	14.3M	12.5M	15.5M	18.9M	1.6M
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	42K
Total Assets	893.5M	974.8M	940.4M	1.1B	1.1B	1B	818.4M	207M	165.8M	134.4M	116.7M	26M	30.9M	5.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	24.6M	13M	13.4M	14.4M	7.3M	4.4M	6.6M	6.3M	6.2M	3M	3.6M	3.3M	3.3M	2.1M
Accounts Payable	24.6M	13M	13.4M	14.4M	7.3M	4.4M	5.8M	6.3M	6.2M	3M	3.6M	3.3M	3.3M	2.1M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	842K	0.0	0.0	0.0	0.0	0.0	0.0	-2.1M
Accrued Expenses	0.0	59.6M	40M	21.7M	21.2M	14.5M	37.6M	24M	20.4M	13.1M	7.3M	3.9M	2.1M	0.0
Short Term Debt	0.0	2.5M	0.0	430K	1M	1.2M	0.0	0.0	0.0	0.0	8.9M	10.4M	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	842K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12K	0.0	0.0	0.0
Other Current Liabilities	76.7M	0.0	20.6M	35.8M	33.8M	29.6M	13.5M	115K	95K	883K	516K	2.6M	33K	12M
Total Current Liabilities	101.3M	75.1M	74M	72.4M	63.4M	49.7M	57.7M	30.4M	26.8M	16.9M	20.4M	20.2M	5.5M	14.1M
NON-CURRENT LIABILITIES
Long Term Debt	35.8M	0.0	282.8M	281.4M	280M	189.4M	0.0	0.0	0.0	0.0	765K	9M	17.5M	0.0
Deferred Tax Liabilities (Non-Current)	441K	6.9M	7.1M	79M	86.4M	10.5M	9.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-4M	22.4M	13.8M	10.3M	9.5M	7M	5.2M	2.7M	846K	159K	343K	157.8M	156.9M	0.0
Total Non-Current Liabilities	136.1M	132.7M	404.6M	471.8M	478.3M	288.4M	87.4M	2.7M	846K	159K	1.1M	166.7M	174.4M	0.0
Capital Lease Obligations	103.9M	103.4M	101M	101.1M	102.3M	81.4M	72.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	237.3M	207.8M	478.6M	544.2M	541.7M	338.1M	145.1M	33.1M	27.6M	17.1M	21.5M	186.9M	179.9M	14.1M
SHAREHOLDERS' EQUITY
Treasury Stock	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	-132K	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	116.7M	157.4M	156.2M	127.2M
Common Stock	58K	56K	49K	48K	47K	45K	44K	36K	35K	34K	32K	6K	5K	5K
Additional Paid-In Capital	1.6B	1.5B	1.1B	997.5M	952.4M	976.6M	861.7M	378.4M	331.1M	308.8M	291.9M	8.2M	6.1M	0.0
Retained Earnings	-933.1M	-745.4M	-599.1M	-464.4M	-365.2M	-310.1M	-189.7M	-205.1M	-192.2M	-192.1M	-196.6M	-159.4M	-147.2M	-134.6M
Accumulated Other Comprehensive Income/Loss	3.3M	2.6M	1.2M	-3M	15K	1M	1.3M	738K	-591K	648K	51K	44K	2K	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-157.4M	-156.2M	4.6M
Total Stockholders' Equity	656.2M	766.9M	461.8M	530M	587.2M	667.4M	673.3M	173.9M	138.2M	117.3M	95.2M	-151.3M	-141.3M	-2.9M
Total Equity	656.2M	766.9M	461.8M	530M	587.2M	667.4M	673.3M	173.9M	138.2M	117.3M	95.2M	-160.9M	-149M	-9M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.6M	-7.7M	-6.2M
SUMMARY
Total Liabilities & Equity	893.5M	974.8M	940.4M	1.1B	1.1B	1B	818.4M	207M	165.8M	134.4M	116.7M	26M	30.9M	0.0
Total Investments	191.8M	149.3M	202M	240.2M	322.8M	317.3M	111.6M	110.7M	94.5M	89.3M	69.6M	0.0	0.0	0.0
Total Debt	139.6M	105.9M	383.7M	382.9M	383.4M	272M	72.6M	0.0	0.0	0.0	9.7M	19.4M	17.5M	0.0
Net Debt	48.8M	-63.8M	290.3M	263.4M	282.7M	175.4M	10.2M	-29.8M	-24.5M	-6.5M	-11.9M	17M	10.8M	-1.7M
Shares Outstanding	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040	57,406,040

SEC Filings

GKOS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 16, 2026	May 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 17, 2026	February 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	October 31, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 203 filings

Related Guides

Blog Categories

Continue your GKOS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.